Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

News

Dr. Reddy’s wins CPHI & PMEC India Award for developing a continuous API manufacturing process.

Dr. Reddy’s wins CPHI & PMEC India Award for developing a continuous API manufacturing process.

Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) has won the CPHI & PMEC India Award in the category R&D Excellence. The recognition highlights Dr. Reddy’s pioneering work developing a continuous API manufacturing process. This includes the successful implementation of flow chemistry and the end-to- end continuous manufacturing of a drug substance at a commercial scale of approximately 300 kg API/day. This innovative process is significantly faster than the traditional batch-to-batch method, with three chemical conversions now happening in less than two minutes, compared to hours in the batch process.

Commenting on the recognition, Deepak Sapra, Head of API and Services, said, “At Dr. Reddy’s, our focus is on accelerating access, advancing cutting-edge science, and promoting sustainability. Transitioning from batch-to-batch API manufacturing to continuous manufacturing provides significant benefits. It enables us to scale production to meet patient demand while reducing our environmental impact through a greener approach. This award is a testament to the dedication of our R&D team and highlights our commitment to investing in science and technology, nurturing talented scientists, and fostering innovation in product development.”

Contact Us

Please fill in the following form and we'll get back to you shortly.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.